Transcatheter Pulmonary Valve Market Size, Share, Growth, and Industry Analysis, By Type (Balloon-Expanded, Self-Expanded), By Application (Cardiac Anomaly, Pulmonary Atresia, Pulmonary Stenosis, Pulmonary Regurgitation, Tetralogy of Fallot, Truncus Arteriosus, Others), Regional Insights and Forecast To 2032

• 

   Request a Free Sample To Get More Information on this Market

TRANSCATHETER PULMONARY VALVE MARKET REPORT OVERVIEW

global transcatheter pulmonary valve market size was USD 0.04 billion in 2023 and market is projected to touch USD 0.05 billion by 2032 at CAGR 3.4% during the forecast period.

A transcatheter pulmonary valve (TPV) is a medical device used to replace a damaged or diseased pulmonary valve in the heart. The TPV is inserted into the heart through a small hole in the chest and then pushed out of the way so the old pulmonary valve can be removed. The new TPV is then placed in place and secured in place.

The market is primarily driven by the prevalence of various cardiovascular diseases such as rheumatic heart disease, hypertensive heart disease, cerebrovascular disease and inflammatory heart disease. Growing population suffering from valvular heart diseases and increasing demand for pulmonary valve replacement are some of the major factors expected to increase the demand for transcatheter valves during the forecast period.

COVID-19 IMPACT

"Market Growth Restrained by Pandemic due to Supply Chain Disruptions"

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

The pandemic has had a significant impact on the entire healthcare industry, including the cardiovascular sector. Disruptions caused by COVID-19 such as delay of elective procedures, restrictions on non-emergency healthcare services and diversion of healthcare resources to manage the pandemic have adversely affected the transcatheter valve market. Transcatheter valves are often used in minimally invasive procedures in patients with severe valvular heart disease. The limitations and challenges imposed by the pandemic resulted in patients requiring transcatheter procedures accessing health services, delayed diagnoses and delayed surgeries.

LATEST TRENDS

"Growing Adoption Of Transcatheter Aortic Valve Replacement Procedures To Expand Market Growth"

The latest trend in the market for Transcatheter Aortic Valve Replacement (TAVR) Procedures is growing. TAVR is a minimally invasive surgical technique used to replace a diseased aortic valve with a prosthesis, usually delivered through a catheter. This technique has gained considerable popularity due to its advantages over traditional open-heart surgery, including shorter recovery time, lower risk of complications, and improved patient outcomes. The increased adoption of TAVR procedures is due to advances in valve design, delivery systems, and operator experience that have broadened patient eligibility criteria to allow treatment of a variety of aortic valve diseases. This trend highlights the shift toward less invasive approaches to cardiac procedures and the increasing acceptance of TAVR as a primary treatment option for patients with aortic valve disease.

TRANSCATHETER PULMONARY VALVE MARKET SEGMENTATION

By Type

Based on type the global market can be categorized into Balloon-Expanded, Self-Expanded.

• Balloon-expandable intravascular valves have been successfully used in adults to preserve ductal walls after coronary and peripheral enlargement. In the treatment of congenital heart disease, stenotic vascular lesions that tend to narrow after dilation have been treated with balloon-expanding stents.

• Many self-expanding valves and leaflets are marketed in different parts of the world. Patients with stenotic pulmonary arteries, obstructive right ventricular outflow tract and coarctation of the aorta were then treated with self-expanding valves. Because of their flexibility and adaptability, self-expanding stents have been used in a variety of clinical applications, including the gastrointestinal, respiratory, and cardiovascular systems.

By Application

Based on application the global market can be categorized into Cardiac Anomaly, Pulmonary Atresia, Pulmonary Stenosis, Pulmonary Regurgitation, Tetralogy of Fallot, Truncus Arteriosus, Others.

Congenital heart disease (CHD), also known as congenital heart disease, congenital cardiovascular malformation, and congenital heart disease, is a birth defect in the structure of the heart or large blood vessels.

pulmonary atresia is a congenital heart defect in which the valve that regulates blood flow from the heart to the lungs does not develop at all.

Pulmonary stenosis is a narrowing of the valve between the right lower chamber of the heart and the pulmonary arteries. With a narrowed heart valve, the leaflets can become thicker or stiffer. This reduces blood flow through the valve.

Pulmonary regurgitation occurs when the pulmonary valve does not close completely and allows blood to leak back into the heart.

Tetralogy of Fallot is a birth defect that affects the normal flow of blood through the heart.

Truncus arteriosus is a congenital defect of the heart. This occurs when a blood vessel in the developing baby's heart does not completely separate during development, leaving a connection between the aorta and the pulmonary artery.

DRIVING FACTORS

"Increasing Number Of Patients Suffering From Various Cardiovascular Diseases Augment The Market Growth"

Increasing number of patients suffering from various cardiovascular diseases such as coronary heart disease, heart failure, hypertension and many others is one of the major reasons fueling the growth of the global transcatheter heart valve replacement market. Cardiovascular diseases cause aortic valve dysfunction. Therefore, this increases the demand for effective valve replacement methods. Growing investment in the healthcare sector to strengthen the medical system is fueling the global transcatheter pulmonary valve market growth. Technological advancements and advancements in the transcatheter aortic valve replacement procedure are expected to support market growth globally.

"Increasing Adoption Of Minimally Invasive Surgeries To Reduce The Duration Of Hospitalization And Healthcare Costs Foster The Market Growth"

The increasing adoption of minimally invasive surgeries to reduce the duration of hospitalization and healthcare costs is projected to fuel the global transcatheter pulmonary valve market growth. The ever-increasing geriatric population along with the rise in valvular heart diseases will contribute to the significant growth of the market during the forecast period. Advanced device manufacturers are emphasizing extensive research and development to develop more modern and minimally invasive methods to treat patients, positively shaping the development of the global transcatheter heart valve replacement market during the forecast period.

RESTRAINING FACTORS

"Limited Reimbursement For Transcatheter Valve Procedures Restraining Market Growth"

One of the factors restraining the global market for transcatheter valve procedures is the limited reimbursement for these procedures. Although transcatheter procedures have gained approval and demonstrated clinical benefit, reimbursement practices and coverage vary among health systems and regions. Lack of comprehensive reimbursement coverage may prevent widespread adoption of transcatheter valve procedures, particularly in areas with limited health care funding and insurance coverage. Addressing reimbursement issues and expanding coverage options can help overcome this limitation and ensure equal access to transcatheter interventions for patients worldwide.

• 

   Request a Free Sample To Get Analysis on Major Geographic Market

TRANSCATHETER PULMONARY VALVE MARKET REGIONAL INSIGHTS

"North America Dominating the Market due to Increasing Patient Awareness Of Advanced Treatment Options"

The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa.

North America dominated the globaltranscatheter pulmonary valve market share in terms of revenue. TPV is an established technology and has been used to treat heart failure for decades. However, the high cost of these devices may prevent their adoption in some areas. North America is expected to be one of the fastest growing markets during the forecast period due to increasing patient awareness of advanced treatment options, improving healthcare infrastructure, prevalence of heart disease and per capita income improving access to healthcare services. facilities and services.

KEY INDUSTRY PLAYERS

"Key Industry Players Shaping the Market through Innovation and Market Expansion"

The Transcatheter Pulmonary Valve market also provides detailed market analysis of each country's growth in healthcare spending on capital equipment, various products installed in the Transcatheter Pulmonary Valve market, the impact of technology using lifetime curves and changes in healthcare regulation. scenarios and their impact on the Transcatheter Pulmonary Valve market. Their strong global presence and brand recognition have contributed to increased consumer trust and loyalty, driving product adoption. Moreover, these industry giants continually invest in research and development, introducing innovative designs, materials, and smart features, catering to evolving consumer needs and preferences. The collective efforts of these major players significantly impact the competitive landscape and future trajectory of the market.

List of Top Transcatheter Pulmonary Valve Companies

• Boston Scientific Corporation (U.S.)
• Braile Biomédica (Brazil)
• Direct Flow Medical (U.S.)
• Edwards Lifesciences Corporation (U.S.)
• JenaValve Technology, Inc. (U.K.)
• Abbott (U.S.)
• SYMETIS (Boston Scientific) (U.S.)
• Colibri Heart Valve, LLC (U.S.)
• VENUS MEDTECH (China)
• XELTIS (Switzerland)

INDUSTRIAL DEVELOPMENT

May 2022: VenusP-ValveTM, Venus Medtechand#039's patented breakthrough Transcatheter Pulmonic Valve Replacement (TPVR) technology, recently received FDA approval in two special cases. Approvalprior to formal clinical trials demonstrates the unique clinical value of the VenusP-ValveTM and #039. VenusP-ValveTM with both flared ends allows stable anchorage and easy delivery without preprocedural explantation. Available in several specifications and with a wide range of applications, the productis suitable for 85% of patients.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.